218 related articles for article (PubMed ID: 35390102)
21. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
22. Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19.
Heide J; Schulte S; Kohsar M; Brehm TT; Herrmann M; Karsten H; Marget M; Peine S; Johansson AM; Sette A; Lütgehetmann M; Kwok WW; Sidney J; Schulze Zur Wiesch J
PLoS Pathog; 2021 Sep; 17(9):e1009842. PubMed ID: 34529740
[TBL] [Abstract][Full Text] [Related]
23. CD8+ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein.
Zhao K; Yang B; Xu Y; Wu C
Vaccine; 2010 Sep; 28(41):6666-74. PubMed ID: 20709007
[TBL] [Abstract][Full Text] [Related]
24. Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay.
Brand I; Gilberg L; Bruger J; Garí M; Wieser A; Eser TM; Frese J; Ahmed MIM; Rubio-Acero R; Guggenbuehl Noller JM; Castelletti N; Diekmannshemke J; Thiesbrummel S; Huynh D; Winter S; Kroidl I; Fuchs C; Hoelscher M; Roider J; Kobold S; Pritsch M; Geldmacher C
Front Immunol; 2021; 12():688436. PubMed ID: 34093595
[TBL] [Abstract][Full Text] [Related]
25. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE
Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303
[TBL] [Abstract][Full Text] [Related]
26. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Sahin U; Muik A; Vogler I; Derhovanessian E; Kranz LM; Vormehr M; Quandt J; Bidmon N; Ulges A; Baum A; Pascal KE; Maurus D; Brachtendorf S; Lörks V; Sikorski J; Koch P; Hilker R; Becker D; Eller AK; Grützner J; Tonigold M; Boesler C; Rosenbaum C; Heesen L; Kühnle MC; Poran A; Dong JZ; Luxemburger U; Kemmer-Brück A; Langer D; Bexon M; Bolte S; Palanche T; Schultz A; Baumann S; Mahiny AJ; Boros G; Reinholz J; Szabó GT; Karikó K; Shi PY; Fontes-Garfias C; Perez JL; Cutler M; Cooper D; Kyratsous CA; Dormitzer PR; Jansen KU; Türeci Ö
Nature; 2021 Jul; 595(7868):572-577. PubMed ID: 34044428
[TBL] [Abstract][Full Text] [Related]
27. COVID-19: S-Peptide RBD
Murdocca M; Citro G; Centanini E; Giannini R; Latini A; Centofanti F; Piano Mortari E; Cocciadiferro D; Novelli A; Bernardini S; Novelli G; Sangiuolo F
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515105
[TBL] [Abstract][Full Text] [Related]
28. Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines.
Yi X; Wang Y; Li Q; Li X; Zhang P; Fu X; Gu S; Zhang D; Liu X; Lou H; Wu Y; Tang L; Hou J; Li Y
J Med Virol; 2023 Mar; 95(3):e28642. PubMed ID: 36890630
[TBL] [Abstract][Full Text] [Related]
29. A novel vaccine based on SARS-CoV-2 CD4
Palatnik-de-Sousa I; Wallace ZS; Cavalcante SC; Ribeiro MPF; Silva JABM; Cavalcante RC; Scheuermann RH; Palatnik-de-Sousa CB
Sci Rep; 2022 Oct; 12(1):16731. PubMed ID: 36202985
[TBL] [Abstract][Full Text] [Related]
30. Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19.
Dang TTT; Anzurez A; Nakayama-Hosoya K; Miki S; Yamashita K; de Souza M; Matano T; Kawana-Tachikawa A
Microbiol Spectr; 2023 Aug; 11(4):e0214323. PubMed ID: 37428088
[TBL] [Abstract][Full Text] [Related]
31. Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.
Yin SW; Zhou Z; Wang JL; Deng YF; Jing H; Qiu Y
Virol J; 2021 Jun; 18(1):126. PubMed ID: 34118952
[TBL] [Abstract][Full Text] [Related]
32. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
Tortorella C; Aiello A; Gasperini C; Agrati C; Castilletti C; Ruggieri S; Meschi S; Matusali G; Colavita F; Farroni C; Cuzzi G; Cimini E; Tartaglia E; Vanini V; Prosperini L; Haggiag S; Galgani S; Quartuccio ME; Salmi A; Repele F; Altera AMG; Cristofanelli F; D'Abramo A; Bevilacqua N; Corpolongo A; Puro V; Vaia F; Capobianchi MR; Ippolito G; Nicastri E; Goletti D;
Neurology; 2022 Feb; 98(5):e541-e554. PubMed ID: 34810244
[TBL] [Abstract][Full Text] [Related]
33. High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4
Coulon PG; Prakash S; Dhanushkodi NR; Srivastava R; Zayou L; Tifrea DF; Edwards RA; Figueroa CJ; Schubl SD; Hsieh L; Nesburn AB; Kuppermann BD; Bahraoui E; Vahed H; Gil D; Jones TM; Ulmer JB; BenMohamed L
Front Immunol; 2024; 15():1343716. PubMed ID: 38605956
[TBL] [Abstract][Full Text] [Related]
34. Limited Recognition of Highly Conserved Regions of SARS-CoV-2.
Swaminathan S; Lineburg KE; Ambalathingal GR; Crooks P; Grant EJ; Mohan SV; Raju J; Panikkar A; Le Texier L; Tong ZWM; Chew KY; Neller MA; Short KR; Gowda H; Gras S; Khanna R; Smith C
Microbiol Spectr; 2022 Feb; 10(1):e0278021. PubMed ID: 35196796
[TBL] [Abstract][Full Text] [Related]
35. Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients.
Tornesello AL; Botti C; Micillo A; Labonia F; Arpino S; Isgrò MA; Meola S; Russo L; Cavalcanti E; Sale S; Nicastro C; Atripaldi L; Starita N; Cerasuolo A; Reimer U; Holenya P; Buonaguro L; Buonaguro FM; Tornesello ML
J Transl Med; 2023 Feb; 21(1):123. PubMed ID: 36788606
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 memory B and T cell profiles in mild COVID-19 convalescent patients.
Gurevich M; Zilkha-Falb R; Sonis P; Magalashvili D; Menascu S; Flechter S; Dolev M; Mandel M; Achiron A
Int J Infect Dis; 2022 Feb; 115():208-214. PubMed ID: 34896265
[TBL] [Abstract][Full Text] [Related]
38. Successive Site Translocating Inoculation Improved T Cell Responses Elicited by a DNA Vaccine Encoding SARS-CoV-2 S Protein.
Tian X; Zhang Y; He Z; Li S; Yan D; Zhu Z; Wan Y; Wang W
Front Immunol; 2022; 13():875236. PubMed ID: 35514964
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.
Filippini F; Giacomelli M; Bazzani C; Fredi M; Semeraro P; Tomasi C; Franceschini F; Caruso A; Cavazzana I; Giagulli C
BMC Med; 2023 Jun; 21(1):210. PubMed ID: 37316832
[TBL] [Abstract][Full Text] [Related]
40. Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension.
Zeng Q; Li YZ; Dong SY; Chen ZT; Gao XY; Zhang H; Huang G; Xu Y
Front Immunol; 2020; 11():596684. PubMed ID: 33362779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
